These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28359247)

  • 1. Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships.
    Zhao L; Au JL; Wientjes MG
    Curr Cancer Drug Targets; 2017; 17(8):735-755. PubMed ID: 28359247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fitting models for the joint action of two drugs using SAS.
    Whitehead A; Whitehead J; Todd S; Zhou Y; Smith MK
    Pharm Stat; 2008; 7(4):272-84. PubMed ID: 17979217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction index and different methods for determining drug interaction in combination therapy.
    Lee JJ; Kong M; Ayers GD; Lotan R
    J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel dose-response curves in combination experiments.
    Sühnel J
    Bull Math Biol; 1998 Mar; 60(2):197-213. PubMed ID: 9559575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.
    Boik JC; Newman RA; Boik RJ
    Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of methods for evaluating drug-drug interaction.
    Zhao L; Au JL; Wientjes MG
    Front Biosci (Elite Ed); 2010 Jan; 2(1):241-9. PubMed ID: 20036874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of non-linear combination effect terms for drug-drug interactions.
    Koch G; Schropp J; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2016 Oct; 43(5):461-79. PubMed ID: 27638639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying Emax model and bivariate thin plate splines to assess drug interactions.
    Kong M; Lee JJ
    Front Biosci (Elite Ed); 2010 Jan; 2(1):279-92. PubMed ID: 20036878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed Beam Murine Harderian Gland Tumorigenesis: Predicted Dose-Effect Relationships if neither Synergism nor Antagonism Occurs.
    Siranart N; Blakely EA; Cheng A; Handa N; Sachs RK
    Radiat Res; 2016 Dec; 186(6):577-591. PubMed ID: 27874325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Combinations: Tests and Analysis with Isoboles.
    Tallarida RJ
    Curr Protoc Pharmacol; 2016 Mar; 72():9.19.1-9.19.19. PubMed ID: 26995550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A generalized response surface model with varying relative potency for assessing drug interaction.
    Kong M; Lee JJ
    Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing drug additivity based on monotherapies.
    Yang H; Novick SJ; Zhao W
    Pharm Stat; 2015; 14(4):332-40. PubMed ID: 25962689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations.
    Tallarida RJ; Raffa RB
    Pharmacol Ther; 2010 Aug; 127(2):165-74. PubMed ID: 20546783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing for additivity at select mixture groups of interest based on statistical equivalence testing methods.
    Stork LG; Gennings C; Carchman RA; Carter WH; Pounds J; Mumtaz M
    Risk Anal; 2006 Dec; 26(6):1601-12. PubMed ID: 17184400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2018; 9():31. PubMed ID: 29467650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical modeling of the effects of drug combinations.
    Plummer JL; Short TG
    J Pharmacol Methods; 1990 Jul; 23(4):297-309. PubMed ID: 2196402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.
    Kashif M; Andersson C; Mansoori S; Larsson R; Nygren P; Gustafsson MG
    Oncotarget; 2017 Nov; 8(61):103952-103967. PubMed ID: 29262612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.
    Zhao L; Wientjes MG; Au JL
    Clin Cancer Res; 2004 Dec; 10(23):7994-8004. PubMed ID: 15585635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental design and statistical analysis for three-drug combination studies.
    Fang HB; Chen X; Pei XY; Grant S; Tan M
    Stat Methods Med Res; 2017 Jun; 26(3):1261-1280. PubMed ID: 25744107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.
    Van der Borght K; Tourny A; Bagdziunas R; Thas O; Nazarov M; Turner H; Verbist B; Ceulemans H
    Sci Rep; 2017 Dec; 7(1):17935. PubMed ID: 29263342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.